(Reuters) - MUMBAI, July 23 - Indian drug maker Dr. Reddy's
Laboratories Ltd. on Monday missed expectations with
a 30.5 percent rise in first quarter net profit, although
demand for cheaper generic drugs was strong as countries look
to cut healthcare costs.
"We remain confident about our performance. This year it
will be all-round secular growth, traditional businesses are
showing good potential. There could be mix of organic and
inorganic growth," Chief Executive G.V. Prasad told Reuters.
Read more at Reuters.com Market News
Laboratories Ltd. on Monday missed expectations with
a 30.5 percent rise in first quarter net profit, although
demand for cheaper generic drugs was strong as countries look
to cut healthcare costs.
"We remain confident about our performance. This year it
will be all-round secular growth, traditional businesses are
showing good potential. There could be mix of organic and
inorganic growth," Chief Executive G.V. Prasad told Reuters.
Read more at Reuters.com Market News
No comments:
Post a Comment